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(p = 0.26); and olanzapine vs. risperidone 1.084 (p =
0.87). Furthermore, adjusted odds ratios of being treated
with a lipid-lowering agent were: atypical vs. typical
1.553 (p = 0.46); risperidone vs. typical 1.711 (p = 0.42);
olanzapine vs. typical 1.474 (p = 0.55); and olanzapine
vs. risperidone 0.775 (p = 0.66). CONCLUSION: Based
on a claims database, 1-year incidence of hyperlipidemia
was generally comparable in schizophrenia patients
receiving treatment with typical antipsychotics, olanzap-
ine or risperidone, though typical-treated patients had
numerically lower incidence compared to those atypical-
treated patients.
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OBJECTIVES: To investigate the association between
sexual dysfunction and nonadherence with antipsychotic
therapy in individuals with schizophrenia. METHODS:
In June 2001, 842 individuals with schizophrenia com-
pleted a self-administered questionnaire that included
questions about the side effects of antipsychotic therapy.
Respondents rated frequency of sexual dysfunction as 
a medication side effect, as well as the degree of dis-
tress and general satisfaction with sexual health and
sexual relationships. Therapeutic nonadherence (non-
compliance) was scored by the self-reported frequency of
missed or skipped antipsychotic doses in an average week.
The association between sexual dysfunction and adher-
ence was evaluated through bivariate analysis and a mul-
tivariate linear regression model, which included Drug
Attitude Inventory (DAI) scores, demographic factors,
and the use of other classes of psychotropic medications.
RESULTS: Among self-reported side effects, distress from
sexual dysfunction was very common. It proved second
only to weight gain in the degree of distress reported by
respondents. A negative association was also found
between reported sexual dysfunction and satisfaction
with sexual health and sexual relationships (P < 0.001).
Sexual dysfunction was associated with self-reported 
nonadherence, both in bivariate analysis (P = 0.024) and
multivariate linear regression (P = 0.035). CONCLU-
SION: In this survey, sexual dysfunction was associated
with reduced adherence to antipsychotic therapy. These
data underscore the importance of assessing side 
effects related to sexual function in patients receiving
antipsychotics.
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OBJECTIVE: To evaluate sample differences associated
with recruiting strategies in a study of people with 
schizophrenia. METHODS: In June 2000 and 2001, 
participants were identiﬁed through Community Mental
Health Centers (CMHC) and chapters of the National
Alliance for the Mentally Ill (NAMI) for a study designed
to understand, explain, and predict the healthcare 
attitudes and behaviors of people with schizophrenia.
Data were collected using self-administered question-
naires. RESULTS: As expected, CMHC (n = 416) and
NAMI (n = 430) respondents differed demographically.
CMHC respondents were more likely to be older (p <
0.001), non-white (p = 0.002), living in group homes (p
< 0.001), and concentrated in urban regions of the
country (Northeast and West, p < 0.001). CMHC respon-
dents were less likely than NAMI recruits to participate
in productive activities (p < 0.001). However, respondents
from both facilities had similar health histories. They
experienced schizophrenia symptoms for similar dura-
tions and had similar symptom severity, as measured by
the Psychological General Well-Being (PGWB) scale. The
two groups were also equally as likely to be overweight
or obese, diagnosed with high cholesterol, and to use
alcohol. CMHC and NAMI respondents also had similar
patterns of care. They were equally as likely to have been
hospitalized in the past six months and to be insured by
Medicaid. Most respondents from both groups were
treated with atypical antipsychotics and received mental
healthcare from community mental health centers. The
groups had almost identical attitudes about medication
compliance (p = 0.989), as measured by the Drug Atti-
tude Inventory (DAI). They also had similar medication
compliance behaviors; 32% of CMHC recruits and 38%
from NAMI organizations reported at least occasionally
missing their psychotropic medication (p = 0.118). 
CONCLUSION: Despite large demographic differences
between respondents recruited through NAMI and
CMHC, there were few differences in health history, and
no signiﬁcant differences in patterns of schizophrenia
care.
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